Scott Gettinger

Summary

Affiliation: Yale University
Country: USA

Publications

  1. doi request reprint Targeted therapy in advanced non-small-cell lung cancer
    Scott Gettinger
    Section of Medical Oncology, Department of Internal Medicine, Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA
    Semin Respir Crit Care Med 29:291-301. 2008
  2. doi request reprint Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
    Scott N Gettinger
    Yale School of Medicine, Yale Cancer Center, New Haven, CT, USA Electronic address
    Lancet Oncol 17:1683-1696. 2016
  3. doi request reprint PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?
    Scott Gettinger
    Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut
    Clin Cancer Res 22:4539-41. 2016
  4. doi request reprint Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
    Scott Gettinger
    Scott Gettinger, Yale Cancer Center, New Haven, CT Naiyer A Rizvi and Matthew D Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY Laura Q Chow, University of Washington, Seattle, WA Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD Neal Ready, Duke University Medical Center, Durham, NC David E Gerber, University of Texas Southwestern Medical Center, Dallas, TX Frances A Shepherd, Princess Margaret Cancer Centre, Toronto Rosalyn A Juergens, Juravinski Cancer Centre at McMaster University, Hamilton Scott A Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada Scott Antonia, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL Jonathan W Goldman, University of California, Los Angeles, Los Angeles, CA and Faith E Nathan, Yun Shen, and Christopher T Harbison, Bristol Myers Squibb, Princeton, NJ
    J Clin Oncol 34:2980-7. 2016
  5. pmc Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
    Scott N Gettinger
    Scott N Gettinger and Mario Sznol, Yale Cancer Center, New Haven, CT Leora Horn, David P Carbone, and Jeffrey A Sosman, Vanderbilt University Medical Center David R Spigel, Sarah Cannon Research Institute Tennessee Oncology, Nashville, TN Leena Gandhi, David M Jackman, and F Stephen Hodi, Dana Farber Cancer Institute Rebecca S Heist and Lecia V Sequist, Massachusetts General Hospital Cancer Center David F McDermott, Beth Israel Deaconess Medical Center, Boston, MA Scott J Antonia and Mary C Pinder Schenck, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL Naiyer A Rizvi, Richard D Carvajal, and Matthew D Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY John D Powderly, Carolina BioOncology Institute, Huntersville, NC David C Smith, University of Michigan, Ann Arbor, MI Philip Leming, Christ Hospital Cancer Center, Cincinnati, OH Suzanne L Topalian, Drew M Pardoll, and Julie R Brahmer, Sidney Kimmel Comprehensive Cancer Center, Servizio di Radiologia
    J Clin Oncol 33:2004-12. 2015
  6. pmc Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer
    Jaclyn Flanigan
    Yale Cancer Center Yale University School of Medicine New Haven, CT, USA
    Biologics 4:237-43. 2010
  7. doi request reprint A decade of advances in treatment for advanced non-small cell lung cancer
    Scott Gettinger
    Division of Medical Oncology, Yale University School of Medicine, 333 Cedar Street, FMP 127, New Haven, CT 06520, USA
    Clin Chest Med 32:839-51. 2011
  8. pmc High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology
    Valsamo K Anagnostou
    Department of Pathology, Yale University School of Medicine, New Haven, CT, USA
    BMC Cancer 10:186. 2010
  9. pmc Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Sci Transl Med 3:75ra26. 2011
  10. doi request reprint Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
    Naiyer A Rizvi
    Naiyer A Rizvi and Matthew D Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY Julie R Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD Rosalyn A Juergens, Juravinski Cancer Centre at McMaster University, Hamilton Scott A Laurie, Ottawa Hospital Cancer Centre, Ottawa Frances A Shepherd, Princess Margaret Cancer Centre, Toronto, Ontario, Canada Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA Scott Gettinger, Yale Cancer Center, New Haven, CT Laura Q Chow, University of Washington, Seattle, WA David E Gerber, University of Texas Southwestern Medical Center, Dallas, TX Jonathan W Goldman, University of California, Los Angeles, Los Angeles, CA Allen C Chen, Yun Shen, Faith E Nathan, and Christopher T Harbison, Bristol Myers Squibb, Princeton, NJ and Scott Antonia, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL
    J Clin Oncol 34:2969-79. 2016

Detail Information

Publications18

  1. doi request reprint Targeted therapy in advanced non-small-cell lung cancer
    Scott Gettinger
    Section of Medical Oncology, Department of Internal Medicine, Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA
    Semin Respir Crit Care Med 29:291-301. 2008
    ..Research efforts are currently focusing on tailoring such therapies according to predictive clinical and molecular markers...
  2. doi request reprint Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
    Scott N Gettinger
    Yale School of Medicine, Yale Cancer Center, New Haven, CT, USA Electronic address
    Lancet Oncol 17:1683-1696. 2016
    ..We aimed to assess brigatinib in patients with advanced malignancies, particularly ALK-rearranged NSCLC...
  3. doi request reprint PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?
    Scott Gettinger
    Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut
    Clin Cancer Res 22:4539-41. 2016
    ..Their role in treating EGFR-mutant and ALK-rearranged lung cancer has yet to be determined. Clin Cancer Res; 22(18); 4539-41. ©2016 AACRSee related article by Gainor et al., p. 4585. ..
  4. doi request reprint Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
    Scott Gettinger
    Scott Gettinger, Yale Cancer Center, New Haven, CT Naiyer A Rizvi and Matthew D Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY Laura Q Chow, University of Washington, Seattle, WA Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD Neal Ready, Duke University Medical Center, Durham, NC David E Gerber, University of Texas Southwestern Medical Center, Dallas, TX Frances A Shepherd, Princess Margaret Cancer Centre, Toronto Rosalyn A Juergens, Juravinski Cancer Centre at McMaster University, Hamilton Scott A Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada Scott Antonia, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL Jonathan W Goldman, University of California, Los Angeles, Los Angeles, CA and Faith E Nathan, Yun Shen, and Christopher T Harbison, Bristol Myers Squibb, Princeton, NJ
    J Clin Oncol 34:2980-7. 2016
    ..First-line monotherapy with nivolumab for advanced NSCLC was evaluated in the phase I, multicohort, Checkmate 012 trial...
  5. pmc Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
    Scott N Gettinger
    Scott N Gettinger and Mario Sznol, Yale Cancer Center, New Haven, CT Leora Horn, David P Carbone, and Jeffrey A Sosman, Vanderbilt University Medical Center David R Spigel, Sarah Cannon Research Institute Tennessee Oncology, Nashville, TN Leena Gandhi, David M Jackman, and F Stephen Hodi, Dana Farber Cancer Institute Rebecca S Heist and Lecia V Sequist, Massachusetts General Hospital Cancer Center David F McDermott, Beth Israel Deaconess Medical Center, Boston, MA Scott J Antonia and Mary C Pinder Schenck, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL Naiyer A Rizvi, Richard D Carvajal, and Matthew D Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY John D Powderly, Carolina BioOncology Institute, Huntersville, NC David C Smith, University of Michigan, Ann Arbor, MI Philip Leming, Christ Hospital Cancer Center, Cincinnati, OH Suzanne L Topalian, Drew M Pardoll, and Julie R Brahmer, Sidney Kimmel Comprehensive Cancer Center, Servizio di Radiologia
    J Clin Oncol 33:2004-12. 2015
    ..We report overall survival (OS), response durability, and long-term safety in patients with non-small-cell lung cancer (NSCLC) receiving nivolumab in this trial...
  6. pmc Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer
    Jaclyn Flanigan
    Yale Cancer Center Yale University School of Medicine New Haven, CT, USA
    Biologics 4:237-43. 2010
    ..This report will review completed and ongoing NSCLC clinical trials evaluating vandetanib, and speculate on the future of this agent in NSCLC...
  7. doi request reprint A decade of advances in treatment for advanced non-small cell lung cancer
    Scott Gettinger
    Division of Medical Oncology, Yale University School of Medicine, 333 Cedar Street, FMP 127, New Haven, CT 06520, USA
    Clin Chest Med 32:839-51. 2011
    ..Several other biomarkers are the focus of ongoing prospective randomized clinical trials customizing both traditional chemotherapy and newer molecularly targeted agents...
  8. pmc High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology
    Valsamo K Anagnostou
    Department of Pathology, Yale University School of Medicine, New Haven, CT, USA
    BMC Cancer 10:186. 2010
    ..Bcl-2 has been investigated as a prognostic factor in non small cell lung cancer (NSCLC) patients with conflicting results...
  9. pmc Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Sci Transl Med 3:75ra26. 2011
    ..Collectively, these results deepen our understanding of resistance to EGFR inhibitors and underscore the importance of repeatedly assessing cancers throughout the course of the disease...
  10. doi request reprint Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
    Naiyer A Rizvi
    Naiyer A Rizvi and Matthew D Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY Julie R Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD Rosalyn A Juergens, Juravinski Cancer Centre at McMaster University, Hamilton Scott A Laurie, Ottawa Hospital Cancer Centre, Ottawa Frances A Shepherd, Princess Margaret Cancer Centre, Toronto, Ontario, Canada Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA Scott Gettinger, Yale Cancer Center, New Haven, CT Laura Q Chow, University of Washington, Seattle, WA David E Gerber, University of Texas Southwestern Medical Center, Dallas, TX Jonathan W Goldman, University of California, Los Angeles, Los Angeles, CA Allen C Chen, Yun Shen, Faith E Nathan, and Christopher T Harbison, Bristol Myers Squibb, Princeton, NJ and Scott Antonia, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL
    J Clin Oncol 34:2969-79. 2016
    ..Here, we report results for nivolumab plus platinum-based doublet chemotherapy (PT-DC)...
  11. pmc High SOX2 levels predict better outcome in non-small cell lung carcinomas
    Vamsidhar Velcheti
    Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut, USA
    PLoS ONE 8:e61427. 2013
    ..The aim of the present study was to evaluate SOX2 expression in NSCLC and determine the relationship with clinico-pathological variables and outcome...
  12. pmc Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors
    William P Tew
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 16:358-66. 2010
    ..To determine the maximum tolerated dose or maximal administered dose and pharmacokinetic and safety profiles of s.c. administered vascular endothelial growth factor Trap (aflibercept), a novel antiangiogenic agent...
  13. pmc Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    J Clin Oncol 28:4953-60. 2010
    ..We studied the activity of IPI-504 after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced, molecularly defined non-small-cell lung cancer (NSCLC)...
  14. pmc Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer
    Katerina Politi
    Departments of Pathology and Medicine Section of Medical Oncology, Yale University School of Medicine and Yale Cancer Center, New Haven, Connecticut
    Clin Cancer Res 20:5576-8. 2014
    ..Different mutants exhibit differential sensitivity to ALK inhibitors. Matching the mutational profile of the tumor with the appropriate ALK inhibitor is likely to be important to maximize benefit for patients...
  15. pmc Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations
    Yelena Y Janjigian
    Thoracic Oncology and Gastrointestinal Oncology Services, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York Weill Cornell Medical College, New York, New York
    Cancer Discov 4:1036-45. 2014
    ....
  16. doi request reprint High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma
    Valsamo K Anagnostou
    Department of Pathology, Section of Medical Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06520 8023, USA
    Clin Cancer Res 15:4157-64. 2009
    ..Here, we quantitatively assessed mTOR protein expression in two large data sets to investigate the impact of mTOR expression on patient survival...
  17. ncbi request reprint Treatment of lung cancer in older patients
    Lynn T Tanoue
    Section of Pulmonary and Critical Care Medicine, Yale School of Medicine, 333 Cedar St, New Haven, CT 06520, USA
    Clin Chest Med 28:735-49, vi. 2007
    ....
  18. ncbi request reprint Complications of therapy in cancer patients: Case 2. Scrotal ulceration during all-trans-retinoic acid therapy for acute promyelocytic leukemia
    Scott Gettinger
    Beth Israel Medical Center, New York, NY, USA
    J Clin Oncol 22:4648-9. 2004